Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dermal Ulcer Treatment with Autologous Fibrin Glue (DUALFIG)
jRCTs052190052Completed
- Sponsor
- Asahi Kasei Corporation
- Start
- Apr 2020
- Modality
- Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of autologous fibrin glue in Cutaneous ulcer, stasis ulcer, diabetic foot ulcer (DFU) and 1 more (2 arms), sponsored by Asahi Kasei Corporation. Primary endpoint: Improvement rate of ulcer surface area at 4 weeks. Started Apr 2020; status: completed.
02
Drugs
autologous fibrin glue
03
Conditions
Cutaneous ulcerstasis ulcerdiabetic foot ulcer (DFU)Vasculitic Ulcer
Beyond the preview
Go deeper on jRCTs052190052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs052190052.